Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

Other illness

• Evidence of Ischemic Heart Disease as determined by study cardiologist.
• Significant Valvular Disease. (AS with AVA <1.5 and severe AR and MR)
• History of Familial Cardiomyopathy.
• History of Infiltrative cardiomyopathy or restrictive cardiomyopathy.
• NYHA class IV heart failure.
• Unstable or life-threatening arrhythmia.
• Mechanical or Bioprosthetic heart valve.
• Autoimmune disorders on current immunosuppressive therapy.
• Active infection not responding to appropriate therapy as determined by Study Chair.

Lab values

• For patients not on anticoagulants, INR>1.5

Other

• Recent documented myocarditis within 2 months of enrollment.
• Presence of left ventricular thrombus as documented by echocardiography or left ventriculogram.
• Liver function tests > 3 x upper limit of normal.
• Inotropic dependence.
• Cardiogenic shock.
• Breastfeeding and/or pregnant women.
• Trastuzumab treatment within the last 3 months.
• Automatic implantable cardioverter defibrillator (AICD) placement within the last 30 days.
• AICD firing within the last 30 days.

• Patients with LVEF </= 40% documented from treatment with anthracyclines for any malignancy at any dose at any time without evidence of other causes of cardiomyopathy.
• Age >/= 18 and </= 90 years of age. English and non-English speaking patients are eligible.
• Documented NYHA class I, II and III.
• For patients who have received trastuzumab: Persistent LV dysfunction must be present 90 days after discontinuation of trastuzumab.
• Able to perform 6 minute walk test.
• Been treated with appropriate maximal medical therapy for heart failure.
• Patient or legally authorized representative able to sign informed consent.